MX2017013687A - Polipeptidos dirigidos a la fusion de vih. - Google Patents
Polipeptidos dirigidos a la fusion de vih.Info
- Publication number
- MX2017013687A MX2017013687A MX2017013687A MX2017013687A MX2017013687A MX 2017013687 A MX2017013687 A MX 2017013687A MX 2017013687 A MX2017013687 A MX 2017013687A MX 2017013687 A MX2017013687 A MX 2017013687A MX 2017013687 A MX2017013687 A MX 2017013687A
- Authority
- MX
- Mexico
- Prior art keywords
- hiv fusion
- polypeptides
- targeting hiv
- polypeptides targeting
- fibronectin
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 230000004927 fusion Effects 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 230000008685 targeting Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 108010067306 Fibronectins Proteins 0.000 abstract 2
- 102000016359 Fibronectins Human genes 0.000 abstract 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
Abstract
La invención se refiere a polipóptidos que comprenden una porción de fijación a CD4, una porción de fijación a gp41, una porción inhibidora peptídica de la fusión de VIH y combinaciones de estas. Más específicamente, la presente invención se refiere a polipóptidos que comprenden una proteína del dominio de andamiaje a base de fibronectina que se fija a CD4, una proteína del dominio de andamiaje a base de fibronectina que se fija al dominio N17 de gp41 y un inhibidor peptídico de la fusión de VIH, o combinaciones de estos. La invención también se refiere al uso de las proteínas innovadoras en aplicaciones terapéuticas para tratar el VIH.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562152271P | 2015-04-24 | 2015-04-24 | |
US201562257474P | 2015-11-19 | 2015-11-19 | |
PCT/US2016/027424 WO2016171980A1 (en) | 2015-04-24 | 2016-04-14 | Polypeptides targeting hiv fusion |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017013687A true MX2017013687A (es) | 2018-07-06 |
Family
ID=55809237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017013687A MX2017013687A (es) | 2015-04-24 | 2016-04-14 | Polipeptidos dirigidos a la fusion de vih. |
Country Status (25)
Country | Link |
---|---|
US (2) | US10407490B2 (es) |
EP (2) | EP3985020A1 (es) |
JP (3) | JP6894846B2 (es) |
KR (1) | KR20170138558A (es) |
CN (1) | CN107922474A (es) |
AU (2) | AU2016252008B2 (es) |
BR (1) | BR112017022790A2 (es) |
CA (1) | CA2983276A1 (es) |
CL (1) | CL2017002687A1 (es) |
CO (1) | CO2017011583A2 (es) |
CR (1) | CR20170482A (es) |
DO (1) | DOP2017000246A (es) |
EA (1) | EA035332B1 (es) |
ES (1) | ES2884267T3 (es) |
HK (1) | HK1243432A1 (es) |
IL (1) | IL255122A0 (es) |
MA (2) | MA56222A (es) |
MX (1) | MX2017013687A (es) |
PE (1) | PE20180162A1 (es) |
PH (1) | PH12017501914A1 (es) |
PT (1) | PT3286212T (es) |
SG (1) | SG11201708441RA (es) |
TW (1) | TW201643185A (es) |
UY (1) | UY36650A (es) |
WO (1) | WO2016171980A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106755100A (zh) * | 2017-02-20 | 2017-05-31 | 李因传 | 可控性hiv‑1基因组靶向编辑***和其靶向载运*** |
JP2021507717A (ja) * | 2017-12-18 | 2021-02-25 | ビーブ、ヘルスケア、ユーケー、(ナンバー5)、リミテッドViiv Healthcare Uk (No.5) Limited | 抗原結合性ポリペプチド |
CN108997482A (zh) * | 2018-08-09 | 2018-12-14 | 东莞市朋志生物科技有限公司 | 用于检测hiv-1的合成肽 |
WO2021081515A2 (en) * | 2019-10-25 | 2021-04-29 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of human immunodeficiency virus |
CN117980465A (zh) * | 2021-08-30 | 2024-05-03 | 康霖生物科技(杭州)有限公司 | 一种用于艾滋病病毒感染基因治疗的基因序列构建体 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
JP3692542B2 (ja) | 1997-01-21 | 2005-09-07 | ザ ジェネラル ホスピタル コーポレーション | Rna−蛋白質の融合体を用いた蛋白質の選抜 |
US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
AU2265701A (en) * | 1999-12-16 | 2001-06-25 | Tanox, Inc. | Anti-hiv-1 conjugates for treatment of hiv disease |
US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
AU2001277867B2 (en) | 2000-07-11 | 2006-12-07 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
MXPA05002851A (es) * | 2002-09-27 | 2005-09-08 | Tanox Inc | Composiciones sinergicas para la prevencion y el tratamiento del sindrome de inmunodeficiencia adquirida. |
ES2551682T3 (es) | 2002-11-08 | 2015-11-23 | Ablynx N.V. | Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos |
HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
US20090022720A1 (en) * | 2007-07-20 | 2009-01-22 | Stephan Fischer | Conjugate of an antibody against CD4 and antifusogenic peptides |
AU2008345424A1 (en) | 2007-12-27 | 2009-07-09 | Novartis Ag | Improved fibronectin-based binding molecules and their use |
ES2620285T3 (es) | 2008-05-02 | 2017-06-28 | Novartis Ag | Moléculas de unión con base en fibronectina mejorada y usos de las mismas |
MX2011004550A (es) | 2008-10-31 | 2011-07-20 | Centocor Ortho Biotech Inc | Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos. |
GB0920944D0 (en) * | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
WO2011077093A1 (en) * | 2009-12-22 | 2011-06-30 | Aarhus Universitet | Bivalent molecules for hiv entry inhibition |
EP3424949A1 (en) * | 2010-04-13 | 2019-01-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind pcsk9 |
TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
MX2012012736A (es) * | 2010-05-07 | 2013-02-26 | Hoffmann La Roche | Metodo de diagnostico para la deteccion de celulas ex vivo. |
CN103380143B (zh) | 2010-12-22 | 2016-01-06 | 百时美施贵宝公司 | 结合il-23的基于纤连蛋白的支架结构域蛋白质 |
CA2834577A1 (en) | 2011-05-23 | 2012-11-29 | Phylogica Limited | Method of determining, identifying or isolating cell-penetrating peptides |
EP4151785A1 (en) | 2011-09-27 | 2023-03-22 | Janssen Biotech, Inc. | Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces |
WO2014120891A2 (en) * | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
US20160152686A1 (en) * | 2013-03-13 | 2016-06-02 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto |
CN103333255A (zh) | 2013-06-28 | 2013-10-02 | 复旦大学 | 一种长效hiv‐1膜融合抑制剂 |
-
2016
- 2016-04-14 WO PCT/US2016/027424 patent/WO2016171980A1/en active Application Filing
- 2016-04-14 MA MA056222A patent/MA56222A/fr unknown
- 2016-04-14 KR KR1020177033985A patent/KR20170138558A/ko unknown
- 2016-04-14 AU AU2016252008A patent/AU2016252008B2/en not_active Ceased
- 2016-04-14 EA EA201792269A patent/EA035332B1/ru not_active IP Right Cessation
- 2016-04-14 BR BR112017022790-8A patent/BR112017022790A2/pt not_active IP Right Cessation
- 2016-04-14 ES ES16718817T patent/ES2884267T3/es active Active
- 2016-04-14 EP EP21176464.2A patent/EP3985020A1/en active Pending
- 2016-04-14 CA CA2983276A patent/CA2983276A1/en not_active Abandoned
- 2016-04-14 PT PT167188176T patent/PT3286212T/pt unknown
- 2016-04-14 MX MX2017013687A patent/MX2017013687A/es unknown
- 2016-04-14 CR CR20170482A patent/CR20170482A/es unknown
- 2016-04-14 SG SG11201708441RA patent/SG11201708441RA/en unknown
- 2016-04-14 EP EP16718817.6A patent/EP3286212B1/en active Active
- 2016-04-14 PE PE2017002311A patent/PE20180162A1/es unknown
- 2016-04-14 CN CN201680036930.XA patent/CN107922474A/zh active Pending
- 2016-04-14 MA MA041943A patent/MA41943A/fr unknown
- 2016-04-14 US US15/568,830 patent/US10407490B2/en active Active
- 2016-04-14 JP JP2017555557A patent/JP6894846B2/ja active Active
- 2016-04-22 UY UY0001036650A patent/UY36650A/es not_active Application Discontinuation
- 2016-04-22 TW TW105112708A patent/TW201643185A/zh unknown
-
2017
- 2017-10-18 IL IL255122A patent/IL255122A0/en unknown
- 2017-10-19 PH PH12017501914A patent/PH12017501914A1/en unknown
- 2017-10-23 DO DO2017000246A patent/DOP2017000246A/es unknown
- 2017-10-23 CL CL2017002687A patent/CL2017002687A1/es unknown
- 2017-11-14 CO CONC2017/0011583A patent/CO2017011583A2/es unknown
-
2018
- 2018-02-28 HK HK18102882.7A patent/HK1243432A1/zh unknown
-
2019
- 2019-08-07 US US16/533,941 patent/US11155602B2/en active Active
- 2019-09-06 AU AU2019226255A patent/AU2019226255A1/en not_active Abandoned
-
2020
- 2020-10-16 JP JP2020174288A patent/JP2021035951A/ja active Pending
-
2023
- 2023-02-03 JP JP2023014947A patent/JP7465378B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501914A1 (en) | Polypeptides targeting hiv fusion | |
MX2022014631A (es) | Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih. | |
CY1124756T1 (el) | Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας | |
EP4230627A3 (en) | Inhibitors of the menin-mll interaction | |
GB2578802B (en) | Programmable DNA binding proteins that increase efficiency and/or specificity of genome targeting in eukaryotic cells for use in therapy | |
PH12021500001A1 (en) | Antibodies that target hiv gp120 and methods of use | |
WO2015109124A3 (en) | Immunomodulatory agents | |
MX2021003475A (es) | Metodos de purificacion de proteinas. | |
WO2018191548A3 (en) | Complement factor d antagonist antibodies and conjugates thereof | |
MX2017014056A (es) | Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos. | |
CR20170020A (es) | Variantes de proteínas de unión al factor h y métodos de uso de estas | |
MX2019003970A (es) | Péptidos de arginasa inmunogénicos. | |
MX2019006943A (es) | Polipéptidos para manejo de infecciones virales. | |
PH12018500159A1 (en) | Constructs targeting psa peptide/mhc complexes and uses thereof | |
CY1125014T1 (el) | Υποκατεστημενα παραγωγα ξανθινης | |
WO2018057967A3 (en) | Constructs targeting hiv peptide/mhc complexes and uses thereof | |
MX2021001361A (es) | Composicion liquida de fibrinogeno humano. | |
PH12018500645A1 (en) | Hiv antibody compositions and methods of use | |
AR104390A1 (es) | Polipéptidos dirigidos a la fusión de vih | |
TN2018000137A1 (en) | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection | |
EA201991733A1 (ru) | Фармацевтические композиции для комбинированной терапии | |
EA201992151A1 (ru) | Фармацевтические композиции для комбинированной терапии | |
WO2015134854A3 (en) | Small molecule vif dimerization antagonists as anti-hiv agents and for use as hiv/aids therapeutics |